Histidine

Histidine

SCHEMBL1996749

N[C@@H](Cc1c[nH]cn1)C(=O)O.N[C@@H](Cc1ccc(OC(=O)[C@@H](N)Cc2c[nH]c3ccccc23)cc1)C(=O)O

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.57
KDM4E B2RXH2 3/20 0.57
MAPT P10636 3/20 0.57
MEN1 O00255 2/20 0.57
LMNA P02545 2/20 0.57
TSHR P16473 2/20 0.57
BLM P54132 2/20 0.57
PMP22 Q01453 2/20 0.57
MPO P05164 1/20 0.57
HIF1A Q16665 1/20 0.57
HSP90AA1 P07900 1/20 0.52
HSP90AB1 P08238 1/20 0.52
LTA4H P09960 1/20 0.52
PLA2G2A P14555 1/20 0.52
TACR1 P25103 2/20 0.47
ERAP1 Q9NZ08 3/20 0.45
ERAP2 Q6P179 2/20 0.45
LNPEP Q9UIQ6 2/20 0.45
SCN9A Q15858 3/20 0.44
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tryptophan SCHEMBL2689669 1.00 KMT2A (0.57) KMT2AKDM4EMAPTMEN1LMNA
SCHEMBL1897500 0.97 MEN1 (0.53) KMT2AKDM4EMAPTMEN1LMNA
Tryptophan SCHEMBL8634349 0.90 KMT2A (0.68) KMT2AKDM4EMAPTMEN1LMNA
Dl-Tryptophan SCHEMBL8634348 0.90 KMT2A (0.68) KMT2AKDM4EMAPTMEN1LMNA
SCHEMBL597229 0.90 KMT2A (0.71) KMT2AKDM4EMAPTMEN1LMNA
SCHEMBL6032937 0.90 KMT2A (0.71) KMT2AKDM4EMAPTMEN1LMNA
Phenylalanine SCHEMBL10381280 0.89 KMT2A (0.70) KMT2AKDM4EMAPTMEN1LMNA
Tryptophan SCHEMBL1996751 0.88 KMT2A (0.63) KMT2AKDM4EMAPTMEN1LMNA
Dl-Tryptophan SCHEMBL1996746 0.88 KMT2A (0.63) KMT2AKDM4EMAPTMEN1LMNA
Tryptophan SCHEMBL6390462 0.88 KMT2A (0.55) KMT2AKDM4EMAPTMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2337577-A1 USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH ANTICANCER AGENTS The Administrators of the Tulane Educational Fund (US) 2011-06-29 EP disclosed
WO-2010036936-A2 USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH ANTICANCER AGENTS THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2010-04-01 WO disclosed
EP-1320594-A2 EXBB-EXBD-TONB GENE CLUSTER OF PSEUDOMONAS PUTIDA DOT-T1E CONFERRING TOLERANCE TO AROMATIC COMPOUNDS AND RESISTANCE TO ANTIBIOTICS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2003-06-25 EP disclosed
WO-2002029034-A2 EXBB-EXBD-TONB GENE CLUSTER OF PSEUDOMONAS PUTIDA DOT-T1E CONFERRING TOLERANCE TO AROMATIC COMPOUNDS AND RESISTANCE TO ANTIBIOTICS NORTH CAROLINA STATE UNIVERSITY (US) 2002-04-11 WO disclosed